Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan W Partin

Showing results (61-70 of 349) with videos related to

Pageof 35
Sort By:
The Journal of Urology|October 9, 2003
The evolving role of docetaxel in the management of androgen independent prostate cancerMasood A Khan, Michael A Carducci, Alan W Partin
Reviews in Urology|October 23, 2014
Best of the 2014 AUA Annual Meeting: Highlights From the 2014 American Urological Association Annual Meeting, May 16-21, 2014, Orlando, FLAdam J M Kern, Alan W Partin, Ellen Shapiro
BJU International|December 22, 2004
Docetaxel in androgen-independent prostate cancer: an updateMasood A Khan, Michael A Carducci, Alan W Partin
Urology|November 20, 2003
Expectant management of localized prostate cancerMasood A Khan, Alan W Partin, H Ballentine Carter
Urology|December 3, 2014
Extent of extraprostatic extension independently influences biochemical recurrence-free survival: evidence for further pT3 subclassificationMark W Ball, Alan W Partin, Jonathan I Epstein
Urology|September 6, 2005
Kinetics of tumor growth of prostate carcinoma estimated using prostate-specific antigenAlexander M Truskinovsky, Alan W Partin, Martin H Kroll
Cancer|March 29, 2002
Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomyGanesh V Raj, Alan W Partin, Thomas J Polascik
Cancer|September 5, 2002
Validation of a biopsy-based pathologic algorithm for predicting lymph node metastases in patients with clinically localized prostate carcinomaAlexander Haese, Jonathan I Epstein, Hartwig Huland, et al.
Urology|December 11, 2007
Contemporary evaluation of the D'amico risk classification of prostate cancerDavid J Hernandez, Matthew E Nielsen, Misop Han, et al.
The Journal of Urology|May 7, 2002
Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores?Danil V Makarov, Harriete Sanderson, Alan W Partin, et al.
Pageof 35

Showing results (61-70 of 349) with videos related to

Sort By:
Pageof 35
The Journal of Urology|October 9, 2003
The evolving role of docetaxel in the management of androgen independent prostate cancerMasood A Khan, Michael A Carducci, Alan W Partin
Reviews in Urology|October 23, 2014
Best of the 2014 AUA Annual Meeting: Highlights From the 2014 American Urological Association Annual Meeting, May 16-21, 2014, Orlando, FLAdam J M Kern, Alan W Partin, Ellen Shapiro
BJU International|December 22, 2004
Docetaxel in androgen-independent prostate cancer: an updateMasood A Khan, Michael A Carducci, Alan W Partin
Urology|November 20, 2003
Expectant management of localized prostate cancerMasood A Khan, Alan W Partin, H Ballentine Carter
Urology|December 3, 2014
Extent of extraprostatic extension independently influences biochemical recurrence-free survival: evidence for further pT3 subclassificationMark W Ball, Alan W Partin, Jonathan I Epstein
Urology|September 6, 2005
Kinetics of tumor growth of prostate carcinoma estimated using prostate-specific antigenAlexander M Truskinovsky, Alan W Partin, Martin H Kroll
Cancer|March 29, 2002
Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomyGanesh V Raj, Alan W Partin, Thomas J Polascik
Cancer|September 5, 2002
Validation of a biopsy-based pathologic algorithm for predicting lymph node metastases in patients with clinically localized prostate carcinomaAlexander Haese, Jonathan I Epstein, Hartwig Huland, et al.
Urology|December 11, 2007
Contemporary evaluation of the D'amico risk classification of prostate cancerDavid J Hernandez, Matthew E Nielsen, Misop Han, et al.
The Journal of Urology|May 7, 2002
Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores?Danil V Makarov, Harriete Sanderson, Alan W Partin, et al.
Pageof 35